-+ 0.00%
-+ 0.00%
-+ 0.00%

STAAR Surgical (STAA) Returns To Profit, Is The Stock Still Cheap?

Simply Wall St·11/15/2026 10:25:27
Listen to the news

STAAR Surgical (STAA) just reported third quarter and nine month 2026 results, returning to profit for the year to date even as quarterly sales and earnings eased compared with the same period last year.

STAAR Surgical shares trade at US$26.39, with a 30 day share price return of 24.07% and a 90 day gain of 9.55%, yet the 5 year total shareholder return of 76.02% decline shows longer term holders are still under water.

See how STAAR Surgical compares to other healthcare names by reviewing the hand-picked 36 healthcare AI stocks that are also wrestling with growth, profitability, and execution risk.

STAAR Surgical has rallied hard off the lows, yet the current US$26.39 price still sits below both analyst targets and intrinsic value estimates. Is that gap a cushion or a warning signal on the latest rebound?

Most Popular Narrative: 5.7% Undervalued

STAAR Surgical's last close at $26.39 sits below the $28.00 fair value in the analyst consensus Narrative on Simply Wall St. This is built from pooled forecasts and a 7.6% discount rate rather than a single opinion.

The main thing that has to go right is that STAAR Surgical converts its strong position in China and rising ex-China EVO and EVO+ adoption into durable market share gains, while keeping operating expenses near the targeted 2026 level and executing on the Nidau, Switzerland ramp to support margins and supply.

See why 8 investors see STAAR Surgical as 6% undervalued.

Result: Fair Value of $28 (UNDERVALUED)

Still, if EVO adoption in China or the Nidau manufacturing ramp disappoints, the current STAAR Surgical undervaluation story could quickly lose its appeal.

Find out about the key risks to this STAAR Surgical narrative.

Another View On STAAR Surgical's Valuation

The analyst consensus on STAAR Surgical leans on earnings forecasts and a fair value of $28, yet the SWS DCF model points to a future cash flow value of $29.18 with the stock at $26.39. If both methods say it is undervalued, is the risk in the numbers or in execution?

To understand how cash flow assumptions feed into that $29.18 figure, and where they could be wrong in either direction, Look into how the SWS DCF model arrives at its fair value.

STAA Discounted Cash Flow as at Nov 2026
STAA Discounted Cash Flow as at Nov 2026

Next Steps

Mixed messages in the STAAR Surgical story today. If you want to move fast and base your stance on the balance of hard data rather than headlines, start by weighing the 3 key rewards and 1 important warning sign.

Looking for more STAAR Surgical sized opportunities?

Do not stop your research with a single ticker. A broader watchlist built from structured ideas can give you context, options, and better conviction.